Compare Bristol-Myers Squibb Co (BMY) vs FuelCell Energy Inc (FCEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs FuelCell Energy Inc — how do they compare? Bristol-Myers Squibb Co trades at $63.95 (market cap $129.94B), while FuelCell Energy Inc trades at $21.71 (market cap $1.54B). The key difference: Bristol-Myers Squibb Co is far larger — about 84.4× FuelCell Energy Inc's market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while FuelCell Energy Inc pays none. Which is the better fit depends on your goals.
| BMY | FCEL | |
|---|---|---|
Market Cap | $129.94B | $1.54B |
Sector | Health | Industrials |
52-Week High | $65.89 | $36.01 |
52-Week Low | $42.60 | $3.92 |
Enterprise Value | $163.92B | $1.38B |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.
BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.
FCEL trades at $22.16, up 11.75% in the past 24 hours, but remains in a bearish technical trend. The company continues to post significant losses, with a net income margin of -132.41% in 2025, despite recent revenue growth to $158.16M. Analyst sentiment is divided with a 45% buy and 45% hold consensus, and a price target of $20.75. Recent news highlights partnerships and volatility within the hydrogen sector.
The outlook is clouded by persistent unprofitability and negative cash flow from operations, posing substantial risk. Upside potential hinges on successful commercialization of technology and sector tailwinds, but the stock faces headwinds from execution challenges and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About FuelCell Energy Inc
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products, which efficiently convert chemical energy in fuels into electricity through a series of chemical reactions. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company generates a majority of its revenue from the United States followed by South Korea.
Read more on FCEL →
